Vera A. Voronina BioNTech-US BioNTech Biography Publications Institution JoVE Articles Vera A. Voronina Dr. Vera Voronina worked for Regeneron Pharmaceuticals from 2008 until 2020, growing from a Scientist to an Associate Director of a Technology Development group. Her work focused on generation and characterization of mouse lines that produce fully human T cell receptors and antibodies. Prior to joining Regeneron she completed post-doctoral training in cell biology and signaling at the University of Washington, where she identified mechanisms underlying primary ciliary dyskinesia. Dr. Voronina obtained a PhD jointly from the National Cancer Institute and West Virginia University, and her thesis work focused on elucidation of genetic causes of anophthalmia and microphthalmia. Publications Kappa-on-Heavy (KoH) Bodies Are a Distinct Class of Fully-human Antibody-like Therapeutic Agents with Antigen-binding Properties Proceedings of the National Academy of Sciences of the United States of America. 01, 2020 | Pubmed ID: 31879340 The Anti-IgE MAb Omalizumab Induces Adverse Reactions by Engaging Fcγ Receptors The Journal of Clinical Investigation. 03, 2020 | Pubmed ID: 31770111 A Novel Bispecific Antibody Platform to Direct Complement Activity for Efficient Lysis of Target Cells Scientific Reports. 08, 2019 | Pubmed ID: 31427700 Deletion of Adam6 in Mus Musculus Leads to Male Subfertility and Deficits in Sperm Ascent into the Oviduct Biology of Reproduction. 03, 2019 | Pubmed ID: 30289441 Flow Cytometric Characterization of Murine B Cell Development Faith M. Harris*1, Karoline A. Meagher*1, Maggie Zhong1, Benjamin J. Daniel2, Mark Eckersdorff1, Jesse A. Green1, Vera Voronina1, Chunguang Guo1, Andre Limnander3, Lynn E. Macdonald1 1Regeneron Tech Centers, Regeneron Pharmaceuticals, Inc., 2Regeneron Therapeutic Proteins, Regeneron Pharmaceuticals, Inc., 3Immunology and Inflammation, Regeneron Pharmaceuticals, Inc. JoVE 61565 Immunology and Infection
Flow Cytometric Characterization of Murine B Cell Development Faith M. Harris*1, Karoline A. Meagher*1, Maggie Zhong1, Benjamin J. Daniel2, Mark Eckersdorff1, Jesse A. Green1, Vera Voronina1, Chunguang Guo1, Andre Limnander3, Lynn E. Macdonald1 1Regeneron Tech Centers, Regeneron Pharmaceuticals, Inc., 2Regeneron Therapeutic Proteins, Regeneron Pharmaceuticals, Inc., 3Immunology and Inflammation, Regeneron Pharmaceuticals, Inc. JoVE 61565 Immunology and Infection